Royalty Pharma (RPRX) PT Raised to $45 at Goldman Sachs
Tweet Send to a Friend
Goldman Sachs analyst Asad Haider raised the price target on Royalty Pharma (NASDAQ: RPRX) to $45.00 (from $42.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
